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Abstract
Background: The generation of thrombin is a critical process in the formation of venous thrombi. In isolated plasma under
static conditions, phosphatidylserine (PS)-exposing platelets support coagulation factor activation and thrombin generation;
however, their role in supporting coagulation factor binding under shear conditions remains unclear. We sought to
determine where activated factor X (FXa), (pro)thrombin, and fibrin(ogen) are localized in thrombi formed under venous
shear.
Methodology/Principal Findings: Fluorescence microscopy was used to study the accumulation of platelets, FXa,
(pro)thrombin, and fibrin(ogen) in thrombi formed in vitro and in vivo. Co-perfusion of human blood with tissue factor resulted
in formation of visible fibrin at low, but not at high shear rate. At low shear, platelets demonstrated increased Ca
2+ signaling and
PS exposure, and supported binding of FXa and prothrombin. However, once cleaved, (pro)thrombin was observed on fibrin
fibers, covering the whole thrombus. In vivo, wild-type mice were injected with fluorescently labeled coagulation factors and
venous thrombus formation was monitored in mesenteric veins treated with FeCl3.T h r o m b if o r m e din vivo consisted of platelet
aggregates, focal spots of platelets binding FXa, and large areas binding (pro)thrombin and fibrin(ogen).
Conclusions/Significance: FXa bound in a punctate manner to thrombi under shear, while thrombin and fibrin(ogen)
distributed ubiquitously over platelet-fibrin thrombi. During thrombus formation under venous shear, thrombin may
relocate from focal sites of formation (on FXa-binding platelets) to dispersed sites of action (on fibrin fibers).
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Introduction
The application of microscopic imaging technologies to in vivo
models of thrombus formation has provided new fundamental
insight into the roles of platelets and coagulation factors in the
thrombus formation process [1,2,3]. These studies have challenged
the traditional understanding that platelets control arterial
thrombus formation, while the coagulation system is implicated
in venous thrombosis, where shear rates are low. For instance,
exposure of tissue factor (TF) and activation of TF-induced
thrombin generation is now also considered to play a key role in
thrombi formed in the arterial circulation [4,5]. Conversely,
platelets contribute to the thrombotic process in veins by
responding to thrombin and then providing interaction and
activation sites for coagulation factors [6]. In vitro studies indicate
that platelets mediate thrombin generation and coagulation by
exposing phosphatidylserine (PS) on their membrane surface
following prolonged increases in cytosolic Ca
2+ [7,8,9]. PS
provides a binding surface for the assembly of the coagulation
tenase and prothrombinase complexes, which convert factor X
into activated factor X (FXa) and prothrombin into thrombin,
respectively [10,11]. Through static experiments, the concept was
developed that the amount and pattern of thrombin generation
and, hence, of fibrin clot formation, is stringently controlled by
platelets [12,13]. In contrast, other studies have shown that the
formation of fibrin is dependent upon the shear rate, with lower
shear rates supporting more fibrin generation [14,15]. Therefore,
the role of procoagulant platelets in the regulation of thrombus
formation under flow conditions is unclear. In the present paper,
we utilized in vitro and in vivo approaches to evaluate the ability of
PS-exposing platelets to support coagulation factor binding in
thrombi formed under shear flow conditions.
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Ethics Statement
Blood donors gave full informed, written consent in accordance
with the Declaration of Helsinki. Experiments were performed
under approval of the Medical Ethics Committee of Maastricht
University. Animal experiments were approved by the Maastricht
University animal experimental and care committee.
Materials
Alexa Fluor (AF) 647 and Oregon Green (OG488) labeled
annexin A5, AF546 and OG488 labeled human fibrinogen, Fluo-4
acetoxymethyl ester (Fluo-4 AM) and labeled goat anti-rat
antibody were from Invitrogen (Leiden, The Netherlands). Rat
anti-mouse CD41 monoclonal antibody (mAb) and fluorescein
isothiocyanate (FITC) labeled anti-CD61 mAb were from BD
Biosciences (San Diego, CA). FITC-labeled anti-human fibrinogen
antibody was from WAK Chemie (Steinbach, Germany) and the
fibrin-specific mAb (anti-fibrin II b chain, clone T2G1) from
Accurate Chemical & Scientific Corporation (Westbury, NY).
Recombinant tissue factor (TF, Innovin) was purchased from
Dade Behring (Marburg, Germany) and recombinant hirudin
(Refludan) from Schering-Plough (Kenilworth, NJ). Fibrillar
collagen was from Chrono-Log (Havertown, PA). The fluorogenic
thrombin substrate Z-Gly-Gly-Arg aminomethyl coumarin (Z-
GGR-AMC) came from Bachem (Bubendorf, Switzerland),
plasmin from Enzyme Research Laboratories (South Bend, IN),
fibrinogen antiserum from MP Biomedicals (Irvine, CA) and
purified human D-dimer from Cell Sciences (Canton, MA).
Unlabeled wildtype annexin A5, with high-affinity binding to PS,
and the quadruple-mutant, M1234 annexin A5, where all Ca
2+-
dependent binding sites were mutated to abolish binding to PS,
were purchased from Nexins Research (Hoeven, The Nether-
lands). All other reagents were purchased from Sigma-Aldrich (St.
Louis, MO).
Fluorescently Labeled Coagulation Factors
Human prothrombin, thrombin and FXa were purified and
characterized as described previously [16,17]. Purified factors
were active-site labeled with N
a-[(acetylthio)acetyl]-D-Phe-Pro-Arg
chloromethyl ketone, followed by mild treatment with NH2OH
and reaction of the thiol generated with 5- (and 6)-iodoacetamido-
29,79-difluorofluorescein (OG488-iodoacetamide) as described
[16,17]. It was confirmed that all active-site labeled factors lacked
protease activity, but retained normal binding properties [16,17].
Human Whole Blood Platelet Activation and Thrombus
Formation Under Shear
Blood was obtained by venipuncture from healthy volunteers
and collected into a one-tenth volume of trisodium citrate
(129 mmol/L trisodium citrate) or a one-sixth volume of acid
citrate dextrose (80 mmol/L trisodium citrate, 52 mmol/L citric
acid, 183 mmol/L glucose). Glass coverslips or capillaries were
coated with fibrinogen (1 mg/mL) or fibrillar collagen (100 mg/
mL) for 1 hour at room temperature. Coverslips were assembled
into a parallel-plate flow chamber and mounted on the stage of an
inverted fluorescence microscope (Diaphot 200; Nikon, Tokyo,
Japan) [18]. Citrate-anticoagulated human blood was perfused
into the flow chamber via a pulse-free syringe pump. Coagulation
was triggered with a second syringe pump, allowing co-perfusion
at one-tenth of the main flow rate with CaCl2/TF medium
(75 mmol/L CaCl2, 37.5 mmol/L MgCl2 and 50 pmol/L TF).
Blood perfusion rates were selected to result in initial wall shear
rates of 200 s
21, 500 s
21, or 1000 s
21; blood was perfused for a
total of 15 minutes at all shear rates. Phase contrast and
fluorescence images were recorded with a 406 oil immersion
objective using two intensified CCD cameras controlled by
Visitech software (Sunderland, UK), as described [2,18].
Changes in cytosolic [Ca
2+]i of adherent platelets were
measured during whole blood perfusion. Washed platelets from
acid citrate dextrose-anticoagulated blood were loaded with Fluo-
4, as described for Fluo-3 [19], and added to citrate-anticoagu-
lated blood from the same donor to yield 20% fluorescent platelets.
During blood perfusion, fluorescence images were recorded at 4
frames per second. Using Visitech software, image series were
analyzed for regions-of-interest representing one adherent platelet,
to give changes in fluorescence (F) per cell. Pseudo-ratioing of F
traces resulted in F/Fo curves, representing increases in single-cell
fluorescence above baseline and corresponding to increases in
intracellular Ca
2+, [Ca
2+]i [20].
Thrombi formed in flow chambers were labeled for 5 minutes
with indicated OG488-conjugated coagulation factors (0.3–
1 mmol/L) or antibodies (20 mg/mL) in combination with
AF647-annexin A5 (14 nmol/L). After washing with Tyrode-
Hepes buffer (136 mmol/L NaCl, 2.7 mmol/L KCl, 10 mmol/L
Hepes, 2 mmol/L MgCl2, 2 mmol/L CaCl2, 5.6 mmol/L
glucose, 0.1% BSA, 1 U/mL heparin; pH 7.45) to remove
unbound fluorescent probes, thrombi were imaged with a 606
oil objective and confocal laser scanning microscope using a
BioRad-Zeiss 2100 multiphoton system described previously [2].
Control experiments were performed with heat-treated fluorescent
probes, which did not incorporate into the thrombi (data not
shown). Single-color fluorescence scanning images were analyzed
for fluorescence coverage, intensity, and distribution patterns with
Image Pro software (Media Cybernetics, Silverspring, MD). The
pixel overlap of two overlay images with different fluorescence
colors (Pearson’s correlation coefficient, Rr) was also calculated.
This parameter is a value from 21t o+1 which describes the
overlap between two colored patterns and is independent of pixel
intensity values.
Real-Time Measurement of Thrombin Generation During
Whole Blood Flow
Citrate-anticoagulated blood containing the fluorogenic throm-
bin substrate, Z-GGR-AMC (420 mmol/L), was co-perfused with
CaCl2/TF over fibrinogen as described above. After perfusion for
10 minutes at 200 s
21, real-time accumulation of fluorescence due
to substrate cleavage was recorded under stasis. Fluorescent
images were obtained every 2 seconds with Visitech software.
Regions of interest corresponding to the site of a thrombus were
analyzed for fluorescence changes. Traces were then converted
into first-derivative curves using Thrombinoscope (Maastricht,
The Netherlands) software developed for thrombin generation
measurement in plasma systems [21].
Measurement of Fibrin Formation from Whole Blood
Flow
To measure fibrin formed under various flow conditions, blood
was co-perfused with TF/CaCl2 for 15 minutes into fibrinogen- or
collagen-coated capillaries as described above. Following blood
perfusion, capillaries were washed with Tyrode-Hepes buffer, then
treated with lysis buffer (20 mmol/L Tris, 300 mmol/L NaCl,
2 mmol/L EGTA, 2% NP-40, 2 mmol/L PMSF) for 5 minutes,
followed by treatment with plasmin (1 mmol/L) for 1 hour to
degrade fibrin. Eluates from capillaries were collected, separated
by SDS-PAGE (6% acrylamide) and western-immunoblotted with
fibrinogen antiserum for the 200 kDa fibrin degradation product
Coagulation Factors on Thrombi
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curve of purified D-dimer (1–100 ng).
In Vivo Thrombus Formation
Thrombus formation was provoked in mesenteric veins of 4–
5 week old wild-type C57Bl/6 mice, as described [5]. Mice were
anesthetized by subcutaneous injection of ketamine (0.1 mg/g
body weight) and xylazine (0.02 mg/g body weight); anesthesia
was maintained throughout the experiment. Fluorescently labeled
coagulation factors were injected via the tail vein (31–37 mmol/L
in 70 mL of 50 mmol/L Hepes and 125 mmol/L NaCl; pH 7.4).
In selected experiments, mice were injected with OG488- or
AF647-labeled goat anti-rat antibody (40 mg) and rat anti-mouse
CD41 mAb (2.5 mgi n7 0mL saline). Mesenteric vessels (venules
with a diameter of ,100 mm and arterioles with a diameter of
,60 mm [5]) were exteriorized and treated topically with 30 mLo f
500 mmol/L FeCl3. The treatment led to the damage and loss of
the endothelial cell layer in mesenteric veins as previously shown
[5]. Vessels were observed with a 406water immersion objective
on an upright Olympus BX-61WI microscope system (Middlesex,
UK). Low fluorescence intensities were visualized with a CCD
camera and a high-performance GEN III image intensifier [22].
Immediately after FeCl3 application, simultaneous brightfield and
fluorescence images were captured at 30 frames per second by
high-speed shutter and wavelength changing systems [23]. Image
acquisition was controlled by Slidebook 4.10.12 software (Intelli-
gent Imaging Innovations, Denver, CO) [23].
Recorded images were processed with Slidebook software.
Fluorescence intensities were corrected for autofluorescence by
eliminating all pixels with a lower intensity than the average
background intensity (determined per frame for a user-defined
region of interest). Using the threshold criteria, all pixel intensities
greater than the background were integrated. No further image
processing was done. Exported raw images were analyzed by
Metamorph software 7.5.0 (Molecular Devices, Downingtown,
PA) to determine the increase in fluorescence of selected thrombi.
Masks corresponding to the site of the thrombus were created and
sum intensities of pixels above background were calculated. After
background subtraction, pixel sizes .3 of all fluorescence features
above background were listed. Features were grouped according
to pixel size (4–9, 10–30, 31–99, 100–309, etc.), and total numbers
of positive pixels per group were determined.
Statistics
Statistical significance was determined by Tukey’s multiple
comparison test and ANOVA.
Results
Thrombus Formation and Platelet Activation Under Shear
To develop a reproducible method of thrombus formation
under shear, human whole blood was co-perfused with CaCl2/
TF into fibrinogen-coated flow chambers. Imaging after 15
minutes of perfusion revealed that the fibrinogen surface was
covered with platelet-rich thrombi and fibrin fibers at low shear
(200 s
21), while at 500 s
21 only thrombi were formed, and at
1000 s
21 a monolayer of platelets was present (Fig. 1A). In the
presence of the thrombin inhibitor, hirudin, only a monolayer of
platelets was observed on fibrinogen at 200 s
21 (Fig. 1A). To
evaluate the extent of fibrin formation on fibrinogen surfaces,
thrombi were lysed and the fibrin degradation product, D-dimer
was evaluated by western blotting. In accordance with previous
studies [14,15], D-dimer levels were maximal at low shear (200
s
-1), indicating that fibrin formation was greatest at the lowest
shear rate (Fig. 1B). A parallel set of results was observed on
collagen surfaces (Fig. S1). We next aimed to determine if
thrombi formed at 200 s
21 could support thrombin generation.
Blood containing a fluorogenic thrombin substrate, Z-GGR-
AMC, was co-perfused with CaCl2/TF into the fibrinogen-
coated chamber. Following 10 minutes of perfusion at 200 s
21,
thrombi were fluorescently imaged. Measurement of the cleavage
of the substrate (as indicated by an increase in fluorescence)
pointed to a transient accumulation of thrombin, which was
ablated in the presence of hirudin (Fig. 2A,B).
To determine the platelet response during blood perfusion,
platelet activation was monitored by loading cells with Fluo-4, an
intracellular Ca
2+ probe. Fluo-4 loaded cells were added to whole
blood and perfused with CaCl2/TF over fibrinogen. Calcium
responses were monitored with fluorescence microscopy. Adherent
platelets demonstrated an increase in cytosolic Ca
2+ under shear,
with the highest amplitude Ca
2+ response observed at 200 s
21
(Fig. 2C-E). The increased response at low shear was partially
dependent upon the generation/availability of thrombin, as
hirudin treatment significantly reduced Ca
2+ responses at 200
s
21. As high cytosolic Ca
2+ can lead to PS exposure, adherent
platelets were stained with OG488-annexin A5, which binds PS
with high affinity. The number of PS-exposing platelets was
greatest at low shear, and was reduced in the presence of hirudin
(Fig. 2F). Together, these results demonstrate that platelet-fibrin
Figure 1. Thrombus formation and fibrin deposition on
fibrinogen under shear. Human whole blood was co-perfused with
CaCl2/TF over fibrinogen for 15 minutes at a shear rate of 200 s
21, 500
s
21, or 1000 s
21. Experiments were performed in the presence of
vehicle or hirudin (2.9 mmol/L). A, Phase-contrast micrographs of
platelet adhesion and fibrin formation. B, Following perfusion, flow
chambers were washed and sequentially treated with lysis buffer and
plasmin. Samples were analyzed for fibrin formation by western blot
analysis, as measured by the fibrin degradation product, D-dimer. Lysis
of fibrinogen-coated capillaries prior to blood perfusion served as a
control (Blank).
doi:10.1371/journal.pone.0010415.g001
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promote TF-induced thrombin generation.
Characterization of Coagulation Factor Distribution on
Thrombi Under Shear
We next aimed to determine the localization of coagulation
factors and the site of thrombin generation during thrombus
formation. Thrombi were formed by perfusion of whole blood and
CaCl2/TF at 200 s
21 over fibrinogen, and were labeled with
fluorescently labeled coagulation factors or antibodies in combi-
nation with AF647-labeled annexin A5 (Fig. 3A). Staining with
fluorescently labeled anti-CD61 (integrin b3) mAb showed the
presence of platelet aggregates (20–45 mm in size), surrounded by
annexin A5-binding platelets (not shown). We next evaluated the
binding of FXa, which has been shown to assemble on the platelet
surface as part of the prothrombinase complex. The labeling of
OG488-FXa substantially overlapped with PS-exposing (annexin
A5-binding) platelets. Quantitatively, this was demonstrated by a
high Pearson’s overlap coefficient Rr between labels of 0.56
(Fig. 3C). OG488-FXa binding was restricted to small structures,
resulting in a fluorescence surface area coverage of 9.661.2%
(Fig. 3B).
In marked contrast, OG488-prothrombin, a substrate of the
prothrombinase complex, distributed over thrombi and fibrin
fibers. As prothrombin can be enzymatically cleaved into
thrombin in the presence of active proteases, labeling was
performed in the presence of the serine protease inhibitor PPACK.
Our results show that the distribution of OG488-prothrombin in
Figure 2. Thrombin generation and platelet activation under shear. Human whole blood was co-perfused with CaCl2/TF over fibrinogen in
the presence of vehicle or hirudin (2.9 mmol/L). A-B, The fluorogenic thrombin substrate, Z-GGR-AMC (420 mM) was added to whole blood prior to
perfusion. The accumulation of fluorescence from cleaved Z-GGR-AMC after 10 minutes of flow at 200 s
21 is shown. A, Increase in fluorescence
intensity from thrombus area; B, first-derivative curves of transient thrombin generation. C-E, Platelets loaded with the calcium indicator Fluo-4 were
added to whole blood before perfusion. Platelet calcium responses under flow are shown. C, Traces of F/Fo values of platelets after adhesion
representing [Ca
2+]i; D, average F/Fo traces; E, fold increase of Ca
2+ responses during 1 minute of adhesion. F, Following blood perfusion, adherent
cells were labeled with OG488-annexin A5. The graph indicates accumulation of PS-exposing platelets (fraction of platelets staining with OG488-
annexin A5 as a percentage of 200 s
21 control). Mean 6 SEM (n=3–5). *P,0.05.
doi:10.1371/journal.pone.0010415.g002
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of AF647-annexin A5 (Fig. 3A), resulting in an increase in the
overlap coefficient Rr of prothrombin and annexin A5 labeling
(Fig. 3C). Moreover, the OG488-prothrombin fluorescence
surface area coverage was drastically reduced in the presence of
PPACK (Fig. 3B). To confirm that prothrombin cleavage was
responsible for the altered label distribution, we investigated the
binding of OG488-active site-labeled thrombin. Our results
demonstrate that OG488-active site-labeled thrombin bound
ubiquitously to fibrin-platelet structures, as evidenced by a
fluorescence area coverage of 35.064.0% and a low overlap
(Rr=0.10) with annexin A5 (Fig. 3).
Utilizing OG488-labeled human fibrinogen or fluorescently
coupled antibodies to fibrin(ogen), the distribution of fibrin(ogen)
was determined on thrombi formed under shear. Fluorescent
fibrinogen bound ubiquitously to the platelet thrombi and fibrin
fibers (Fig. 4A,B), as evidenced by a high surface area coverage
(45.367.7%) and low overlap with annexin A5 (0.17). Similarly,
fluorescently-labeled antibodies against fibrinogen or fibrin bound
in a ubiquitous manner on platelet-fibrin thrombi, resulting in a
low overlap with annexin A5 (0.20 and 0.12 for anti-fibrinogen
and anti-fibrin antibodies, respectively; Fig. 4C). In contrast, a
substantial overlap was observed when thrombi were dual stained
with OG488-prothrombin and AF547-fibrinogen (Rr=0.79).
To determine the role of PS-exposing platelets in fibrin
generation in the low shear model of thrombus formation, flow
experiments were performed using blood pretreated with wild-type
or mutant annexin A5 (0.28 mmol/L). When blood containing
wild-type annexin A5 was co-perfused with CaCl2/TF over
fibrinogen and post-labeled with OG488-fibrinogen, there was a
marked decrease in OG488-fibrinogen labeling and absence of
fibrin formation (Fig. 5). In contrast, pretreatment of blood with
M1234 annexin A5 mutant (lacking the four Ca
2+ binding sites
required for interaction with PS) had no effect on fibrin formation
or the distribution of OG488-fibrinogen on the thrombus surface
(Fig. 5). Collectively, these results reveal the distinct distribution of
FXa, prothrombin, and thrombin on thrombi formed under shear,
and confirm the important role of exposed PS for fibrin formation
under flow.
Heterogeneous Incorporation of Coagulation Factors in
Venous Thrombi in Vivo
To evaluate the incorporation of coagulation factors into
thrombi formed in vivo, thrombus formation was studied by
brightfield and fluorescence microscopy following FeCl3-induced
damage of mouse mesenteric veins with mean wall shear rates of
,345 s
21 [5]. Video images were recorded following injection of
OG488-labeled fibrinogen, prothrombin, FXa or anti-CD41
(integrin aIIb) mAb. Images showed accumulation of labeled
platelets and coagulation factors following vascular damage (Fig. 6).
Although the rate of label accumulation was similar for all probes,
marked differences were observed in the patterns of label
incorporation (Fig. 6). Whereas labeled fibrinogen and prothrom-
bin distributed as large fluorescent structures of the size of the
whole thrombus, labeling of FXa and platelets (anti-CD41 mAb)
was confined to numerous 15–45 mm sized structures. As
confirmed by morphometric analysis of the label distribution
Figure 3. Localization of factor Xa (FXa) and (pro)thrombin on thrombi formed under shear. Human whole blood was co-perfused with
CaCl2/TF at 200 s
21 over fibrinogen. Thrombi were dual-labeled with AF647-annexin A5 (14 nmol/L, red) and active-site OG488-labeled coagulation
factors (1 mmol/L, green) or an antibody to the integrin b3 (a-CD61, 20 mg/ml, green). Where indicated, serine proteases were inhibited during labeling
with PPACK (40 mmol/L). A, Confocal images in green are shown for OG488-labeled FXa, prothrombin (Prothr), or thrombin (Thr) fluorescence; images
in red indicate annexin A5 binding. B, Fluorescence surface area coverage for each green label and annexin A5. C, Pearson’s correlation coefficient,
showing overlap between PS-exposing platelets and green labels. Mean 6 SEM (n=3–5).
doi:10.1371/journal.pone.0010415.g003
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and prothrombin, but only 25% of labeled platelets and FXa,
accumulated into features of .3100 pixels (Fig. 6C).
Discussion
Our study was designed to investigate the distribution of
coagulation factors on thrombi under shear. Our data demon-
strate that FXa and prothrombin (in the presence of PPACK)
bound in a punctate manner on the thrombus surface under shear,
overlapping substantially with annexin A5-binding, PS-exposing
platelets. This finding is in accord with previous studies using
purified systems under static conditions that have shown that the
tenase and prothrombinase complexes assemble on peripheral
blood cell surfaces [10,24,25,26]. Our observation that fibrin
formation was abrogated in the presence of supraphysiological
concentrations of annexin A5 [27,28], demonstrates the functional
role of coagulation factor interactions with exposed PS during
thrombus formation.
While FXa and prothrombin labeling was punctate, thrombin
and fibrin(ogen) were ubiquitously distributed over fibrin-platelet
structures, with a large surface area coverage and low overlap with
annexin A5. Thrombin is a critical player in blood coagulation
and is known to bind to the platelet surface and to fibrin(ogen)
[13,29,30,31,32]; however, where thrombin is localized during
clot formation is largely unknown. Thrombin interacts with
fibrin(ogen) though multiple low and high affinity binding sites
[33,34]. Importantly, a high affinity thrombin binding site exists
on an alternatively spliced variant of fibrinogen (c9-fibrinogen),
which is present in ,10% of circulating fibrinogen molecules and
becomes incorporated into fibrin [35,36,37]. Thrombin bound to
this high affinity site on fibrin(ogen) has been shown to be
enzymatically active and protected from inhibition by the heparin-
antithrombin complex [33,38]. Therefore, our findings of
thrombin distribution on platelet-fibrin clots, suggest that fibrin
Figure 4. Spatial localization of fibrin(ogen) and procoagulant platelets during thrombus formation. Thrombi were formed by a 15
minute co-perfusion of whole blood and CaCl2/TF at 200 s
21 over fibrinogen. Dual-labeling was with AF647-annexin A5 (14 nmol/L, red) and the
indicated fibrin(ogen) labels (green). A, Confocal fluorescence images in green are shown for OG488-fibrinogen (FG, 0.3 mmol/L), anti-fibrinogen
antibody (a-FG, 20 mg/mL), or anti-fibrin antibody (a-Fibrin, 20 mg/mL). Images in red indicate staining of PS-exposing platelets. B, Fluorescence
surface area coverage for each OG488 label and annexin A5. C, Pearson’s correlation coefficient (Rr), between annexin A5 and each green label. Mean
6 SEM (n=3–5 experiments).
doi:10.1371/journal.pone.0010415.g004
Figure 5. Role of PS-exposing platelets in fibrin formation
during thrombus formation. Thrombi were formed on fibrinogen
by co-perfusion of whole blood and CaCl2/TF at a shear rate of 200
s
21. Blood samples were incubated with vehicle, annexin A5, or
mutant M1234 annexin A5 (each 0.28 mmol/L) before perfusion.
Thrombi were labeled with OG488-fibrinogen (0.3 mmol/L). A,
Representative phase-contrast micrographs of platelets and fibrin
after 15 minutes of perfusion. B, Relative accumulation of labeled
fibrin(ogen). Data are presented as integrated fluorescence intensity
per microscopic field. Results of one representative experiment are
shown.
doi:10.1371/journal.pone.0010415.g005
Coagulation Factors on Thrombi
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results point to an initial binding of prothrombin to the FXa-
containing prothrombinase complex at PS-exposing platelets
(thrombin formation), followed by redistribution of active
thrombin to the platelet-fibrin thrombus.
Previous in vivo experiments with wild-type C57Bl/6 mice have
shown that FeCl3-induced thrombus formation in the mesenteric
venules relies on the exposure of collagen, activation of the TF/
activated factor VII pathway, thrombin, and platelet activation
[2,5]. While exposed extracellular matrix proteins play an essential
role in mediating the first steps of platelet recruitment in damaged
vessels, fibrinogen plays a predominant role in platelet aggregate
formation. Rapid deposition of fibrin(ogen) is observed in FeCl3-
induced damage of mesenteric venules [39], allowing deposited
fibrin(ogen) to become a substrate for subsequent platelet recruit-
ment, adhesion, and aggregation. Under low shear venous
conditions, an essential role has been established for fibrinogen in
supporting platelet aggregation and adhesion to the growing platelet
plug through interactions with aIIbb3 [40,41,42,43]. Our in vitro
work points to a role for fibrin(ogen) in supporting thrombin
localization during thrombus formation. We therefore designed a
series of experiments to characterize the distribution of coagulation
factors on thrombi formed by FeCl3-provoked damage of mesenteric
venules in vivo.I np a r a l l e lw i t ho u rin vitro studies, a punctate
distribution of FXa was observed, in accord with the notion that
FXa binding is localized to the platelet surface during thrombus
formation. Importantly, our in vivo data demonstrate that fibrin(ogen)
and (pro)thrombin incorporated into large structures and were
distributed throughout the thrombi. Taken together, our studies
point to an important role for fibrin(ogen) in retaining the key
coagulation enzyme thrombin on clots formed under shear.
Supporting Information
Figure S1 Thrombus formation and fibrin deposition on collagen
under shear. Human whole blood was co-perfused with CaCl2/TF
over collagen for 15 minutes at a shear rate of 200 s
-1,5 0 0s
-1,o r
1000 s
-1. Experiments were performed in the presence of vehicle or
hirudin (2.9 mmol/L). A, Photo micrographs of platelet adhesion
and fibrin formation. B, Following perfusion, flow chambers were
washed and sequentially treated with lysis buffer and plasmin.
Samples were analyzed for fibrin formation by western blot analysis,
as measured by the fibrin degradation product, D-dimer.
Found at: doi:10.1371/journal.pone.0010415.s001 (2.78 MB TIF)
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